Barrett & Company, Inc. Galectin Therapeutics Inc Transaction History
Barrett & Company, Inc.
- $231 Billion
- Q3 2024
A detailed history of Barrett & Company, Inc. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Barrett & Company, Inc. holds 3,834 shares of GALT stock, worth $4,562. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,834
Previous 3,834
-0.0%
Holding current value
$4,562
Previous $8.67 Million
21.68%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding GALT
# of Institutions
91Shares Held
9.65MCall Options Held
1.16MPut Options Held
1.98M-
Vanguard Group Inc Valley Forge, PA2.13MShares$2.54 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$1.86 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$1.41 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA863KShares$1.03 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$575,0840.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $70.7M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...